

## CURRICULUM VITAE

### INFORMAZIONI PERSONALI

Nome	Maria Grazia Castagna
Qualifica	Professore Associato di Endocrinologia
Amministrazione	Università di Siena
Incarico attuale	Direttore UOC Endocrinologia- Azienda ospedaliero-universitaria Senese

### TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	Laurea in Medicina e Chirurgia con votazione 110/110 e lode , Università di Messina
Specializzazioni	Diploma di Specializzazione in Endocrinologia e Malattie del ricambio con votazione 50/50 e lode, Università di Messina
Iscrizioni ad albi professionali	Ordine dei Medici Chirurghi e degli Odontoiatri della provincia di Crotone
Altri titoli di studio e professionali	Dottorato in Scienze Endocrine e Metaboliche, Università di Pisa
Capacità linguistiche	Lingua madre : Italiano Altra lingua: buona conoscenza dell'inglese scritto e parlato
Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare)	<b>REVISORE SCIENTIFICO DI RIVISTE INTERNAZIONALI:</b> The Journal of Clinical Endocrinology and Metabolism; Journal of Endocrinological Investigation; Thyroid; Nuklearmedizin, European Journal of Endocrinology.  <b>ASSOCIATE EDITOR:</b> -L'endocrinologo - Journal of Endocrinology and Investigation  <b>PREMI E RICONOSCIMENTI</b> <ul style="list-style-type: none"><li>• Gennaio 1992: Vincitrice di borsa di studio semestrale della Fondazione Bonino-Pulejo di Messina presso l'Università degli studi di Firenze, Dipartimento di Endocrinologia diretta dal Prof. M.Serio.</li><li>• Gennaio 2000 : Vincitrice di una borsa di studio annuale della Fondazione Carozza-S.Leonardo-Pollicino della durata di un anno presso l'Università degli studi di Pisa,</li></ul>

Dipartimento di Endocrinologia diretto dal Prof. A.Pinchera.

- Agosto 2001: European Thyroid Association Research Grant
- Dicembre 2001: vincitrice del premio "Miglior presentazione poster" al congresso XIX Giornate Italiane della Tiroide, Bolzano.
- Dicembre 2002: vincitrice del premio "Miglior presentazione poster" al congresso XX Giornate Endocrinologiche Pisane, Pisa.
- Gennaio 2003: Vincitrice di borsa di studio Triennale FIRC 2003-2005 con progetto di ricerca dal titolo " TSH umano ricombinante (rhTSH): studi in vivo e in vitro"

#### MEMBERSHIP

- Società Italiana di Endocrinologia (SIE)
- European Society of Endocrinology (ESE)
- Associazione Italiana della Tiroide (AIT)
- European Thyroid Association (ETA)

**HA PARTECIPATO IN QUALITÀ DI RELATORE A NUMEROSI CONGRESSI NAZIONALI E INTERNAZIONALI.**

#### Publicazioni scientifiche

1. Marialuisa Appetecchia, Rosa Lauretta, Agnese Barnabei, Letizia Pieruzzi, Irene Terrenato, Elisabetta Avedon, Caterina Mian, **Maria Grazia Castagna**, Rossella Elisei, SIE (Italian Society of Endocrinology) Working Group. Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. *Cancer (Basel)*, 11 (10) 2019
2. Tania Pilli, Silvia Cantara, Carlotta Marzocchi, Furio Pacini, Bellur S Prabhakar, **Maria Grazia Castagna**. Vemurafenib May Overcome TNF-related Apoptosis-Inducing Ligand (TRAIL) Resistance in Anaplastic Thyroid Cancer Cells. *Endocrine*, 67 (1), 117-123, 2020
3. Premoli P, Tanda ML, Piantanida E, Veronesi G, Gallo D, Masiello E, Rosetti S, Cusini C, Boi F, Bulla J, Rodia R, Mariotti S, Capelli V, Rotondi M, Magri F, Chiovato L, Rocchi R, Campopiano MC, Elisei R, Vitti P, Barbato F, Pilli T, **Castagna MG**, Pacini F, Bartalena L. Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. *J Endocrinol Invest*. 2019 Jul 20. doi: 10.1007/s40618-019-01088-5
4. Locati LD, Piovesan A, Durante C, Bregni M, **Castagna MG**, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R. Real-world efficacy and safety of

lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. *Eur J Cancer*. 2019 Jul 9;118:35-40. doi: 10.1016/j.ejca.2019.05.031

5. Cantara S, Ricci C, Maino F, Marzocchi C, Pacini F, **Castagna MG** Variants in MCT10 protein do not affect FT3 levels in athyreotic patients. *Endocrine*. 2019 Jul 6. doi: 10.1007/s12020-019-02001-z.
6. Silvia Cantara, Francesco Chiofalo, Cristina Ciuoli, Carlotta Marzocchi, Maria Teresa Dotti, Maccora Carla, **Maria Grazia Castagna**, Fabio Giannini. Rare POMC mutation in a patients with myotonic dystrophy type I and adrenocorticotropin hyperresponse to corticotropin-releasing hormone. e132 *AACE CLINICAL CASE REPORTS* Vol 5 No. 2 March/April 2019.
7. Silvia Cantara, Fabio Maino, Carlotta Marzocchi and **Maria Grazia Castagna**. Fasting enhances TKI efficacy on thyroid cancer cells. *International Journal of Innovative and applied research (IJIAR)* 2019, Volume 7, Issue 01. **IF: 2.85**
8. Pilli T, Cardinale S, Dalmiglio C, Secchi C, Fralassi N, Cevenini G, Di Cairano G, Maino F, Forleo R, Pacini F, **Castagna MG**. Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort. *J Endocrinol Invest*. 2019 Jun;42(6):693-698.
9. Cantara S, Bertelli E, Occhini R, Regoli M, Brillì L, Pacini F, **Castagna MG**, Toti P. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. *Endocrine*. 2019 Apr;64(1):122-129
10. Capezzone M, Secchi C, Fralassi N, Cantara S, Brillì L, Ciuoli C, Pilli T, Maino F, Forleo R, Pacini F, **Castagna MG**. Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma? *J Endocrinol Invest*. 2019 Mar 29.
11. **Castagna MG**, Marzocchi C, Pilli T, Forleo R, Pacini F, Cantara S. MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series. *J Endocrinol Invest*. 2019 Jan;42(1):97-100.
12. Maino F, Cantara S, Forleo R, Pilli T, **Castagna MG**. Clinical significance of type 2 iodothyronine deiodinase polymorphism. *Expert Rev Endocrinol Metab*. 2018 Sep;13(5):273-277.
13. **Castagna MG**, Forleo R, Maino F, Fralassi N, Barbato F, Palmitesta P, Pilli T, Capezzone M, Brillì L, Ciuoli C, Cantara S, Formichi C, Pacini F. Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. *J Endocrinol Invest*. 2018 Sep;41(9):1029-1035.
14. Maino F, Forleo R, Martinelli M, Fralassi N, Barbato F, Pilli T, Capezzone M, Brillì L, Ciuoli C, Di Cairano G, Nigi L,

- Pacini F, **Castagna MG**. Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. *J Clin Endocrinol Metab*. 2018 Jun 1;103(6):2362-2368.
15. Pilli T, Toti P, Occhini R, **Castagna MG**, Cantara S, Caselli M, Cardinale S, Barbagli L, Pacini F. Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes. *J Endocrinol Invest*. 2018 Jun;41(6):703-709.
  16. Guido Sebastiani PhD, Elena Ceccarelli MD, PhD, **Maria Grazia Castagna MD, PhD**, Francesco Dotta, MD. G-protein coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. *Best Pract Res Clin Endocrinol Metab*. 2018 Apr;32(2):201-213. **IF: 4,466**
  17. **Castagna MG**, Forleo R, Maino F, Fralassi N, Barbato F, Palmitesta P, Pilli T, Capezzone M, Brillì L, Ciuoli C, Cantara S, Formichi C, Pacini F. Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. *J Endocrinol Invest*. 2018 Feb 22. doi: 10.1007/s40618-018-0854-8. **IF: 2,633**
  18. Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Moreli S, Torlontan M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Danele L, Fugazzola L, Ceresini G, Bruo R, Rossetto R, Tumino S, Centanni M, Meringolo D, **Castagna MG**, Salvatore D, Nocolucci A, Lucisano G, Filetti S, Durante C, 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. *Endocr Relat Cancer*. 2018 Mar;25(3):L7-L11. doi: 10.1530/ERC-17-0453. **IF: 5,267**
  19. Pilli T, Toti P, Occhini R, **Castagna MG**, Cantara S, Caselli M, Cardinale S, Barbagli L, Pacini F. Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+T lymphocytes. *J Endocrinol Invest*. 2017 Dec 11. doi: 10.1007/s40618-017-0794-8- **IF: 2,633**
  20. Cantara S, Marzocchi C, Pilli T, Cardinale S, Forleo R, **Castagna MG**, Pacini F. Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. *Int J Mol Sci*. 2017 6;18. pii: E775. doi: 10.3390/ijms18040775. **IF: 3,226**
  21. **Castagna MG**, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C, Garbi C, Pacini F, Salvatore D. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. *J Clin Endocrinol Metab*. 2017.1;102:1623-1630. doi: 10.1210/jc.2016-2587 **IF: 5,455**
  22. Cantara S, Marzocchi C, **Castagna MG**, Pacini F. HABP2 G534E variation in familial non-medullary thyroid cancer:

- an Italian series. *J Endocrinol Invest.* 2017;40:557-560. doi: 10.1007/s40618-016-0583-9. **IF: 2,633**
23. Rotondi M, **Castagna MG**, Cappelli C, Ciuoli C, Coperchini F, Chiofalo F, Maino F, Palmitesta P, Chiovato L, Pacini F. Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules. *Eur Thyroid J.* 2016;5:125-31. doi: 10.1159/000445054
  24. **Castagna MG**, Cantara S, Pacini F. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. *J Endocrinol Invest.* 2016 ;39:1087-94. doi: 10.1007/s40618-016-0503-z **IF: 2,633**
  25. **Castagna MG**, Fugazzola L, Maino F, Covelli D, Memmo S, Sestini F, Fioravanti C, Ferraris Fusarini C, Scapellato C, Macchini F, Cevenini G, Pacini F. Reference range of serum calcitonin in pediatric population. *J Clin Endocrinol Metab.* 2015 ;100:1780-4 doi: 10.1210/jc.2014-4508 **IF: 5,455**
  26. **Castagna MG**, Belardini V, Memmo S, Maino F, Di Santo A, Toti P, Ferdinando Carli A, Caruso G, Pacini F. Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series, but not in cytological series: evidence for selection bias. *J Clin Endocrinol Metab.* 2014 ;99:3193-8 doi: 10.1210/jc.2014-4508 **IF: 5,455**
  27. Fast S, Hegedus L, Pacini F, Pinchera A, Leung AM, Vaisman M, Reiners C, Wemeau JL, Huysmans D, Harper W, Rachinsky I, De Souza HN, **Castagna MG**, Antonangeli L, Braverman LE, Corbo R, Düren C, Proust-Lemoine E, Marriott C, Driedger A, Grupe P, Watt T, Magner J, Purvis A, Graf H. Long-term efficacy of modified-release recombinant human TSH (MRrhTSH) augmented radioiodine (<sup>131</sup>I) therapy for benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled dose-selection study. *Thyroid.* 2014;24:727-35. doi: 10.1089/thy.2013.0370 **IF: 5,515**
  28. **Castagna M**, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Cipri C, Belardini V, Brianzoni E, Pacini F (2013). Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. *Eur J Endocrinol.* 2013; 1;169:23-9. doi: 10.1530/EJE-12-0954 **IF: 4,101**
  29. Pacini F, **Castagna M**. Approach to and treatment of differentiated thyroid carcinoma. *Med Clin North Am.* 2012;96:369-83. doi: 10.1016/j.mcna.2012.01.002 **IF: 2,455**
  30. Pacini F, **Castagna M**. New insight in the follow-up strategies of differentiated thyroid cancer. *J Endocrinol Invest.* 2012;35(6 Suppl):36-9 **IF: 2,633**
  31. Cantara S, D'Angeli F, Toti P, Lignitto L, **Castagna M**, Capuano S, Prabhakar BS, Feliciello A, Pacini F.

- Expression of the ring ligase PRAJA2 in thyroid cancer. *TJ Clin Endocrinol Metab.* 2012 ;97:4253-9. doi: 10.1210/jc.2012-2360. **IF:5,455**
32. Pacini F, **Castagna M**, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2012 ;23 Suppl 7:vii110-9. DOI: 10.1093/annonc/mds230 **IF: 11,855**
33. **Castagna M**, Jury HPT, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A, Pacini F. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. *J Endocrinol Invest.* 2011;34e219-23. Doi:10.3275/7571 **IF: 2,633**
34. **Castagna M**, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. *Eur J Endocrinol.* 2011;165:441-6. doi: 10.1530/EJE-11-0466. **IF: 4,101**
35. Graf H, Fast S, Pacini F, Pinchera A, Leung A, Vaisman M, Reiners C, Wemeau JL, Huysmans D, Harper W, Driedger A, de Souza HN, **Castagna M**, Antonangeli L, Braverman L, Corbo R, Duren C, Proust-Lemoine E, Edelbroek MA, Marriott C, Rachinsky I, Grupe P, Watt T, Magner J, Hegedus L. Modified-Release Recombinant Human TSH (MRrhTSH) Augments the Effect of (131)I Therapy in Benign Multinodular Goiter: Results from a Multicenter International, Randomized, Placebo-Controlled Study. *J Clin Endocrinol Metab.* 2011;96:1368-76. doi: 10.1210/jc.2010-1193. **IF: 5,455**
36. Ciuoli C, Brusco L, Theodoropoulou A, **Castagna M**, Neri O, Pasqui L, Pacini F. Effects of Acute Recombinant Human TSH on Serum Ghrelin Levels. *Front Endocrinol (Lausanne).* 2011; 16;2:94. doi: 10.3389/fendo.2011.00094 **IF: 3,675**
37. Pacini F, **Castagna M**, Cipri C, Schlumberger M. Medullary Thyroid Carcinoma. *Clin Oncol (R Coll Radiol).* 2010 ;22:475-85. doi: 10.1016/j.clon.2010.05.002. **IF: 3,236**
38. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Uberta V, Boscaro M, **Castagna M**, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. *Eur J Endocrinol.* 2010;163:301-8. doi: 10.1530/EJE-10-0333 **IF: 4,101**

39. Santini F, Galli G, Maffei M, Fierabracci P, Pelosini C, Marsili A, Giannetti M, **Castagna M**, Checchi S, Molinaro E, Piaggi P, Pacini F, Elisei R, Vitti P, Pinchera A. Acute exogenous TSH administration stimulates leptin secretion in vivo. *Eur J Endocrinol.* 2010;163(1):63-7. doi: 10.1530/EJE-10-0138 **IF: 4,101**
40. Pacini F, **Castagna M**, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010 ;21 Suppl 5:v214-9. doi: 10.1093/annonc/mdq190. **IF: 11,855**
41. Jury HPT, **Castagna M**, Fioravanti C, Cipri C, Brianzoni E, Pacini F. Lack of Association between Urinary Iodine Excretion and Successful Thyroid Ablation in Thyroid Cancer Patients. *J Clin Endocrinol Metab.* 2010;95:230-7. doi: 10.1210/jc.2009-1624. **IF:5,455**
42. Pacini F, **Castagna M**, Brilli L, Pentheroudakis G, ESMO guidelines working group. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol.* 2009 ;20 Suppl 4:143-6. doi: 10.1093/annonc/mdp156. **IF: 11,855**
43. Pacini F, **Castagna M**. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. *Best Pract Res Clin Endocrinol Metab.* 2008;22:1009-21. doi: 10.1016/j.beem.2008.09.014. **IF: 4,466**
44. Pacini F, **Castagna M**, Brilli L, Jost L, ESMO Guidelines Working Group. Differentiated Thyroid Cancer. ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol.* 2008 ;19 Suppl 2:ii99-101. doi: 10.1093/annonc/mdn115. **IF: 11,855**
45. **Castagna M**, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. *J Clin Endocrinol Metab.* 2008; 93:76-81. DOI: 10.1210/jc.2007-1404 **IF: 5,455**
46. Pilli T, Brianzoni E, Capocchetti F, **Castagna M**, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burrioni L, Vattimo A, Cipri C, Pacini F. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2007;92:3542-6. DOI: 10.1210/jc.2007-0225 **IF: 5,455**
47. **Castagna MG**, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, Grasso L, Pacini F, Santini F, Elisei R. Influence of Human Body Composition on Serum Peak Thyrotropin (TSH) after Recombinant Human TSH Administration in Patients with Differentiated Thyroid Carcinoma. *J Clin Endocrinol Metab.* 2005;90:4047-50.

DOI: 10.1210/jc.2005-0534 **IF: 5,455**

48. Elisei R, Romei C, **Castagna MG**, Lisi S, Vivaldi A, Faviana P, Marinò M, Ceccarelli C, Pacini F, Pinchera A. RET-PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously realer by elevated serum thyroglobulin concentration. *Thyroid*. 2005 ;15:1355-61. DOI: 10.1089/thy.2005.15.1355 **IF: 5,515**
49. Santini F, Pinchera A, Marsili A, Ceccarini G, **Castagna M**, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G, Rago T, Mammoli C, Elisei R, Vitti P. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab*. 2005 ;90:124-7. DOI: 10.1210/jc.2005-0534 **IF: 5,455**
50. Biscolla RP, Ugolini C, Sculli M, Bottici V, **Castagna MG**, Romei C, Cosci B, Molinaro E, Faviana P, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. *Thyroid*. 2004;14:946-52. DOI: 10.1089/thy.2004.14.946 **IF: 5,515**
51. Miccoli P, Elisei R, Berti P, Materazzi G, Agate L, **Castagna MG**, Cosci B, Faviana P, Ugolini C, Pinchera A. Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. *J Endocrinol Invest*. 2004;27:557-61. DOI: 10.1007/BF03347478 **IF: 2,633**
52. Vermiglio F, Lo Presti VP, Moleti M, Sidoti M, Tortorella G, Scaffidi G, **Castagna M**, Mattina F, Violi MA, Crisà A, Artemisia A, Trimarchi F. Attention deficit and hyperactivity disorders in the offspring of mothers exposed to mild-moderate iodine deficiency: a possible novel iodine deficiency disorder in developed countries. *J Clin Endocrinol Metab*. 2004;89:6054-60. DOI: 10.1210/jc.2004-0571 **IF: 5,455**
53. Lisi S, Menconi F, Altea MA, Agate L, Molinaro E, **Castagna M**, Taddei D, Grasso L, Pinchera A, Elisei R, Marinò M. Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. *J Endocrinol Invest*. 2004;27:636-42. DOI: 10.1007/BF03347495 **IF: 2,633**
54. Pacini F, Molinaro E, **Castagna MG**, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab*. 2003;88:3668-73. DOI: 10.1210/jc.2002-021925 **IF: 5,455**
55. Vermiglio F, Lo Presti VP, Violi MA, Moleti M, **Castagna M**, Finocchiaro MD, Mattina F, Mandolino M, Zimbaro G, Trimarchi F. Changes in both size and cytological features



- of thyroid nodule after levothyroxine treatment. Clin Endocrinol (Oxf) 2003; 59:347-53. **IF: 3,327**
56. Pacini F, Molinaro E, **Castagna MG**, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A. Ablation of thyroid residues with 30 mCi 131-Iodine: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063-8. DOI: 10.1210/jc.2001-011918 **IF: 5,455**
57. Pacini F, Molinaro E, Lippi F, **Castagna MG**, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A. Prediction of disease status by Recombinant Human TSH-stimulated serum tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5686-90. DOI: 10.1210/jcem.86.12.8065 **IF: 5,455**
58. Vermiglio F, **Castagna MG**, Volnova E, Lo Presti VP, Moleti M, Violi MA, Artemisia A, Trimarchi F. Post Chernobyl increased prevalence of humoral thyroid autoimmunity in children and adolescents from moderately iodine deficient area in Russia. Thyroid. 1999;9:781-6. DOI: 10.1089/thy.1999.9.781 **IF: 5,515**
59. Vermiglio F, Lo Presti VP, **Castagna MG**, Violi MA, Moleti M, Finocchiaro MD, Mattina F, Artemisia A, Trimarchi F. Increased risk of maternal thyroid failure with pregnancy progression in an iodine deficient area with major iodine deficiency disorders. Thyroid. 1999;9:19-24. DOI: 10.1089/thy.1999.9.19 **IF: 5,515**
60. Vermiglio F, Violi MA, Finocchiaro MD, Baldari S, **Castagna MG**, Moleti M, Mattina F, Pio Lo Presti V, Bonanno N, Trimarchi F. Short-term effectiveness of low dose radioiodine ablative treatment of thyroid remnant following thyroidectomy for differentiated thyroid cancer. Thyroid. 1999; 9:387-91. DOI: 10.1089/thy.1999.9.387 **IF: 5,515**

#### PUBBLICAZIONI NON INDICIZZATE

1. F.Pacini, **M.G.Castagna**, E. Guarino. Il nodulo tiroideo: percorso diagnostico-terapeutico. 2007 Medico e Paziente, n° 8.
2. F.Pacini, L.Brilli, **M.G. Castagna**. Carcinoma differenziato della tiroide: diagnosi, terapia e follow-up. Medicinae Doctor. 2007, numero 9 F.
3. Pacini, **M.G.Castagna**. Cancer de la thyroide en Italie: Données épidémiologiques. Santé & Rayonnements Ionisants, 2007, n° 32.
4. Pacini F, **Castagna MG**, Brilli L, Pilli T. Application of Recombinant Human TSH in the diagnosis and treatment of thyroid diseases. Hot Thyroidology (www.hotthyroidology.com), March , No , 2007
5. Pacini F, **Castagna MG**, Brilli L. (2008) Advances in the diagnosis of differentiated thyroid cancer. European

Endocrinology, 4(2):100-102

6. Pacini F, **Castagna MG**, Cipri C. Uso del TSH umano ricombinate (rhTSH) nel follow-up del carcinoma tiroideo differenziato. L'Endocrinologo 2008, Vol 9, Suppl 3.
7. Pacini F, **Castagna MG**. Il follow-up del paziente con carcinoma differenziato della tiroide secondo le linee di consenso internazionali. L'Endocrinologo 2009.
8. Pacini F, **Castagna MG**. Follow-up del paziente con carcinoma differenziato della tiroide secondo le linee guida di consenso internazionali. L'endocrinologo 2010, Vol 11, n°1
9. F. Pacini, **MG Castagna**, Valentina Belardini. Innovazioni nel dosaggio della tireoglobulina circolante nei pazienti con carcinoma differenziato della tiroide. L'endocrinologo 2010, Vol 11, n°6
10. **Castagna MG**. Innovation in the post-surgical management of differentiated thyroid carcinoma. Journal of the Siena Academy of Sciences - Vol.3, pag 13-16 - 2011
11. **Castagna MG**. Significato clinico del dosaggio della tireoglobulina ultrasensibile nel carcinoma tiroideo differenziato. L'endocrinologo 2014, Vol 15, n°2 DOI 10.1007/s40619-014-0018-9
12. **Castagna MG** Il follow-up del carcinoma differenziato della tiroide secondo le linee guida ATA 2016. L'Endocrinologo (2017) 18:48–50 DOI 10.1007/s40619-017-0284-4
13. **Castagna MG**, Maino F. Il controllo nel tempo del carcinoma differenziato della tiroide alla luce delle nuove linee guida. L'Endocrinologo (2017) 18 (1): 48–50
14. **Castagna MG**, **Trimarchi F**. La risposta al trattamento iniziale del carcinoma differenziato della tiroide ne guida la gestione clinica nel tempo. L'Endocrinologo ( 2018), 19(4): 213–214
15. **Castagna MG**, **Pacini F**. Metastasi linfonodali e recidiva del microcarcinoma papillare tiroideo. L'Endocrinologo (2019) 20:202–205
16. **Castagna MG**: Redifferenziazione del carcinoma tiroideo refrattario BRAF mutato con Vemurafenib L'Endocrinologo (2019) 20:384–385
17. **Castagna MG**, Fadda G: Impatto della diagnosi citologica TIR3a sulle decisioni dell'endocrinologo. L'endocrinologo 2020 (in press)

#### CAPITOLI DI LIBRI

1. Pacini F, Molinaro E, **Castagna MG**, Agate L, Pinchera A (2003). Uso del TSH umano ricombinate (rhTSH) nel follow-up diagnostico e terapeutico del carcinoma differenziato differenziato della tiroide. Tumori della tiroide (capitolo 9, ), Mediserve

2. Pacini F, **Castagna MG**, Belardini V (2011). Tumori maligni della tiroide. In: Lenzi A, Lombardi G, Martino E, Vigneti R. Endocrinologia clinica. Torino, Edizione Minerva Medica, ISBN: 9788877116932
3. Pacini F, **Castagna MG**, Belardini V., Memmo S (2011). Neoplasie della tiroide. In: Gasperi M, Ferrara N. Endocrinologia Geriatrica. Società Editrice Universo, ISBN: 9788865150191
4. Pacini F, **Castagna MG** (2012). Differentiated (papillary and follicular) and anaplastic thyroid carcinoma. In: Monaco F. Thyroid disease. Boca Raton: CRC Press, ISBN: 9781439868386
5. **Castagna MG** (2013) Thyroid Cancer of Parafollicular Origin: Medullary Carcinoma. In: Cantara S. Thyroid Cancer. A Clinical Overview and A Useful Laboratory Manual. Bentham Books. ISBN: 9781608057504
6. **Castagna MG**, Brilli L, Pacini F (2016). A case of papillary thyroid cancer without aggressive histological features with nodal metastases detected during follow-up in a younger patients. In: Cooper DS and Durante C. Thyroid cancer- A case-Based Approach. Eds Springer ISBN 978-3-319-22400-8. ISBN 978-3-319-22401-5
7. **Castagna MG**, Brilli L, Pacini F (2016). A case of papillary thyroid cancer without aggressive histological features with nodal metastases in an older patients. In: Cooper DS and Durante C. Thyroid cancer- A case-Based Approach. Eds Springer ISBN 978-3-319-22400-8. ISBN 978-3-319-22401-5
8. Pacini F, Dotta F, Gennari L con la collaborazione di **Castagna MG**, Brilli L, Capezzone M, Ceccarelli E, Di Cairano G, Nigi L, Patti A, Pilli T, Merlotti D. (2017) Patologie endocrine e del metabolismo In: Nuti R. Manuale di Medicina Interna. Edizione Minerva Medica. ISBN: 978-88-7711-860-8
9. Pacini F, **Castagna MG**, Schlumberger M (2018). Differentiated Thyroid Carcinoma of Follicular Origin. In Endocrinology: Thyroid Diseases. Pathogenesis, Diagnosis, and Treatment, edited by Paolo Vitti and Laszlo Hegedus. Springer Edition ISBN 978-3-319-45013-1
10. Pacini F, **Castagna MG** (2018) Radiiodine ablation-current status. In Ujjal K. Mallick Clive Harmer. Practical management of thyroid cancer. A multidisciplinary approach. Springer Edition ISBN 9783319917245
11. Brilli L, Pilli T, Pacini F, **Castagna MG**, (2020). A case of papillary thyroid cancer without aggressive histological features with nodal metastases detected during follow-up in a younger patients. In: Cooper DS

	and Durante C. Thyroid cancer- A case-Based Approach. <i>In press</i>
--	--

Data di compilazione 12 Febbraio 2020

*(L'estensore del curriculum non dovrà apporre la firma. Tale misura è adottata a difesa dei dati personali dell'interessato ai sensi del regolamento UE 2016/679 e del D.Lgs. 196/2003 aggiornato al D.Lgs. n. 101 del 10.08.2018)*

*Il CV è compilato dall'interessato e periodicamente aggiornato sotto la sua diretta responsabilità*